Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new Oxford Sparks animation with Hazel Hall-Roberts (Alzheimer’s Research UK Oxford Drug Discovery Institute) explores how researchers at the University of Oxford are working to discover new treatments for Alzheimer's.

Your beautiful, complex brain is a network of microscopic cells that connect together to form your thoughts and personality, and control your body. The network is fragile and requires constant upkeep, like a garden. The brain has its own gardeners, specialised cells called microglia.

In this new animation, Oxford Sparks look at how researchers at the University of Oxford are developing drug treatments for Alzheimer’s disease, by harnessing the power of the brain’s microglia. Watch the animation below. 

 

Oxford Sparks is an online platform that highlights the scientific research carried out at the University through exciting videos, animations and podcasts aimed at a public audience. Scientists from the Division have worked with Oxford Sparks to produce a variety of digital content that explains their innovative research to a wider audience, including a large number of exciting animations and this new podcast series. 

Find out more

Similar stories

Five ways the pandemic has affected routine medical care

Since the beginning of the pandemic, COVID has infected at least a third of the UK population and is estimated to have factored in the deaths of almost 200,000 people in the UK. But critically, COVID has also had a devastating impact on our healthcare systems. While this was expected, new evidence is beginning to reveal the scope of the issue – in particular the effects for people living with long-term health conditions.

Clinical trials for a malaria vaccine start in Mali and Indonesia

Sanaria Inc. announced that two new Phase 2 trials of its pioneering malaria vaccines have started. The first is in 6- to 10-year-old children living in Bancoumana, Mali, a malarious region of West Africa. The second is in Indonesian soldiers based in Sumatra, Indonesia. The soldiers will be deploying for six to nine months this coming August to an intensely malarious district in eastern Indonesia.

Mechanism of expanding bacteria revealed

A new study published in Nature has identified a potential Achilles heel in the protective layers surrounding Gram-negative bacteria that could aid in the development of next-generation antibiotics.

Oxford to receive £7 million to turn bright ideas into global opportunities

The University of Oxford has been awarded more than £7 million, the highest amount of funding given to organisations across the UK, in the latest round of UK Research and Innovation’s (UKRI) Impact Acceleration Account (IAA) funding - aimed at fueling the best, brightest and most disruptive ideas from Uk research institutions.

Discovery of gene involved in chronic pain creates new treatment target

Oxford researchers have discovered a gene that regulates pain sensitisation by amplifying pain signals within the spinal cord, helping them to understand an important mechanism underlying chronic pain in humans and providing a new treatment target.

Oxford's largest ever study into Varicose veins shows need for surgery is linked to genetics

A new international study by Oxford researchers published in Nature Communications establishes for the first time, a critical genetic risk score to predict the likelihood of patients suffering with Varicose veins to require surgery, as well as pointing the way towards potential new therapies.